FDA Clears AI Tool That Predicts Breast Cancer Recurrence Before Surgery

TumorSight Risk reads a patient's existing breast MRI to estimate, before an operation, how likely her cancer is to come back within five or ten years.

What happened: The FDA has cleared TumorSight Risk, a software tool from SimBioSys built on NVIDIA technology, which its maker calls the first AI tool to estimate breast cancer recurrence risk directly from MRI scans. It's designed for women with hormone receptor-positive, HER2-negative, early-stage breast cancer, which makes up roughly three-quarters of all U.S. breast cancer cases. Unlike many existing recurrence tests, it can deliver a risk estimate before surgery even happens.

Why it matters: After a diagnosis, 'will it come back' is often the first question patients ask. That answer shapes real decisions: whether to add chemotherapy, and whether to keep taking hormone-blocking drugs for five years or longer, treatments that carry real side effects. Getting a personalized estimate earlier, and without extra procedures, could help patients and doctors weigh those trade-offs with more confidence instead of relying only on generalized statistics.

How it works, plainly: TumorSight Risk doesn't require a new scan or biopsy. It reuses the MRI, pathology results and clinical history already collected during diagnosis, and AI examines the tumor and surrounding tissue to produce a score from 0 to 100, sorting patients into low, intermediate or high risk. In a validation study of 2,129 patients across four institutions, high-risk patients had about 3.3 times the recurrence risk of low-risk patients, and each 10-point score increase tracked with a 22% jump in relative risk.

The rollout: The tool is now reaching hospitals and cancer centers nationwide, and SimBioSys says it's working with Medicare, Medicaid and private insurers to secure coverage, meaning cost and access aren't fully settled yet. Mayo Clinic, one of the four validation sites, holds a financial stake in SimBioSys, a detail disclosed in the study. Doctors say the score is meant to sit alongside other tests and clinical judgment, not replace them.